StockData
Exelixis, Inc. logo

Exelixis, Inc. (EXEL) stock

EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/303% above fair value
$68.50+1.40 (+2.09%)

Close on Nov 17, 2026Market cap $16.71BP/E 20.5Yield –

Exelixis cash

Cash and short-term investments held at the end of each period.

Exelixis's cash was $892.02M at Oct 2, 2026. For fiscal 2025 it was $1.06B, down 4.7% from the year before. Over ten years it grew 20.1% a year on average. The highest annual figure on record is $1.48B in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Jan 2, 2026$1.06B-4.7%
FY2024Jan 3, 2025$1.11B+11.7%
FY2023Dec 29, 2023$995.30M-24.0%
FY2022Dec 30, 2022$1.31B-11.7%
FY2021Dec 31, 2021$1.48B+22.8%
FY2020Jan 1, 2021$1.21B+41.5%
FY2019Jan 3, 2020$853.88M+23.0%
FY2018Dec 28, 2018$694.43M+76.7%
FY2017Dec 29, 2017$392.92M-7.3%
FY2016Dec 31, 2016$423.95M+150.9%
FY2015Dec 31, 2015$169.00M+17.1%
FY2014Dec 31, 2014$144.30M-40.5%
FY2013Dec 31, 2013$242.45M-41.1%
FY2012Dec 31, 2012$411.44M+111.8%
FY2011Dec 31, 2011$194.26M+19.4%
FY2010Dec 31, 2010$162.66M+87.4%
FY2009Dec 31, 2009$86.80M-65.0%
FY2008Dec 31, 2008$247.70M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Oct 2, 2026$892.02M-9.8%
Q2 FY2026Jul 3, 2026$839.39M+6.1%
Q1 FY2026Apr 3, 2026$777.21M-24.6%
Q4 FY2025Jan 2, 2026$1.06B-4.7%
Q3 FY2025Oct 3, 2025$988.54M-16.9%
Q2 FY2025Jul 4, 2025$791.10M-21.0%
Q1 FY2025Apr 4, 2025$1.03B+7.1%
Q4 FY2024Jan 3, 2025$1.11B+11.7%
Q3 FY2024Sep 27, 2024$1.19B+7.8%
Q2 FY2024Jun 28, 2024$1.00B-20.9%
Q1 FY2024Mar 29, 2024$963.26M-26.7%
Q4 FY2023Dec 29, 2023$995.30M-24.0%
Q3 FY2023Sep 29, 2023$1.10B-28.7%
Q2 FY2023Jun 30, 2023$1.27B-18.0%
Q1 FY2023Mar 31, 2023$1.31B-17.0%
Q4 FY2022Dec 30, 2022$1.31B-11.7%
Q3 FY2022Sep 30, 2022$1.55B+8.0%
Q2 FY2022Jul 1, 2022$1.55B+10.9%
Q1 FY2022Apr 1, 2022$1.58B+28.3%
Q4 FY2021Dec 31, 2021$1.48B+22.8%
Q3 FY2021Oct 1, 2021$1.43B+20.5%
Q2 FY2021Jul 2, 2021$1.39B+14.7%
Q1 FY2021Apr 2, 2021$1.24B+29.2%
Q4 FY2020Jan 1, 2021$1.21B+41.5%
Q3 FY2020Oct 2, 2020$1.19B+56.2%
Q2 FY2020Jul 3, 2020$1.21B+47.6%
Q1 FY2020Apr 3, 2020$956.00M+19.4%
Q4 FY2019Jan 3, 2020$853.88M+23.0%
Q3 FY2019Sep 27, 2019$761.67M+20.0%
Q2 FY2019Jun 28, 2019$823.22M+64.7%
Q1 FY2019Mar 29, 2019$800.75M+87.6%
Q4 FY2018Dec 28, 2018$694.43M+76.7%
Q3 FY2018Sep 28, 2018$634.62M+72.9%
Q2 FY2018Jun 29, 2018$499.92M+43.1%
Q1 FY2018Mar 30, 2018$426.92M+0.6%
Q4 FY2017Dec 29, 2017$392.92M-7.3%
Q3 FY2017Sep 30, 2017$367.10M–
Q2 FY2017Jun 30, 2017$349.26M–
Q1 FY2017Mar 31, 2017$424.27M–
Q4 FY2016Dec 31, 2016$423.95M–

More Exelixis figures

See a number that looks wrong?